bioAffinity Technologies, Inc. (BIAF) Fair Value 2026

BIAF · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (50/100)

Quick Summary — As of 2026-10-07, bioAffinity Technologies, Inc. (BIAF) trades at $6.06. QOC: 4.9/10. Value Trap Risk: 50/100 (WARN). 1/13 models active.

Key Facts

Ticker
BIAF
Price
$6.06
Quality Score
4.9/10
Value Trap Risk
50/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 50 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give BIAF?

1 Intrinsic Value Models vs. Current Price ($6.06)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $4.38 -27.7%

All Models Active

All 1 models are displayed above.

What Is bioAffinity Technologies, Inc. (BIAF) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, bioAffinity Technologies, Inc.'s intrinsic value is estimated at $4.38. Trading at its current price of $6.06, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -27.7%.

What Do the Models Say About BIAF?

1 of 13 models are currently active for BIAF. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does BIAF Rank in Diagnostics & Research?

Among 50 Diagnostics & Research stocks, BIAF ranks #41 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

bioAffinity Technologies, Inc.'s positioning within the Diagnostics & Research segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is BIAF a Value Trap?

CirclFi's Value Trap algorithm assigns BIAF a score of 50/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for bioAffinity Technologies, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, bioAffinity Technologies, Inc. earns a quality score of 4.9/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BIAF valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BIAF's 1 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy bioAffinity Technologies, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

ADVBAdvanced Biomed Inc.QOC 5.1ISPCiSpecimen Inc.QOC 4.8XWELXWELL, Inc.QOC 5.5FRNMFreenome, Inc.QOC 4.8OPKOPKO Health, Inc.QOC 5.6PRPHProPhase Labs, Inc.QOC 4.7AAgilent Technologies, Inc.QOC 9.1RVTYRevvity, Inc.QOC 7.5MYGNMyriad Genetics, Inc.QOC 6.5IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: ADVB · ISPC · XWEL · FRNM · OPK · PRPH · A · RVTY · MYGN · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to BIAF?

7 companies across all industries closest to BIAF’s Quality of Company score of 4.9/10.

MGRXMangoceuticals, Inc.QOC 4.9SVIASilvia, Inc.QOC 4.9HQLAbrdn Life Sciences InvestorsQOC 4.9CELCCelcuity Inc.QOC 4.9RVTRoyce Small-Cap Trust, Inc.QOC 4.9LPLLG Display Co., Ltd.QOC 4.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MGRX · SVIA · HQL · CELC · RVT · LPL · NVDA

What Else Do Investors Ask About bioAffinity Technologies, Inc.’s Valuation?

What is bioAffinity Technologies, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for bioAffinity Technologies, Inc. (BIAF). The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BIAF overvalued or undervalued right now?

At $6.06, 0 of 1 active models suggest BIAF may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits bioAffinity Technologies, Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 4.9 mean for BIAF?

bioAffinity Technologies, Inc.'s QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BIAF?

CirclFi analyzes BIAF with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is BIAF a value trap in 2026?

bioAffinity Technologies, Inc.'s Value Trap score is 50/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns bioAffinity Technologies, Inc. (BIAF) a Quality of Company score of 4.9/10 across 32 fundamental signals as of 2026-10-07.” Source: circlfi.com/stock/BIAF/ · Methodology
Primary sources for this BIAF valuation
  • Financial statements: bioAffinity Technologies, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001712762) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BIAF as of ; valuations recomputed .